Prostaglandin E receptor subtype EP3 in conjunctival epithelium regulates late-phase reaction of experimental allergic conjunctivitis.
BACKGROUND
We previously demonstrated that the prostaglandin E(2) (PGE(2))-EP3 pathway negatively regulates allergic reactions in a murine allergic asthma model.


OBJECTIVE
We investigated whether the PGE(2)-EP3 pathway also regulates the development of murine experimental allergic conjunctivitis (EAC).


METHODS
The expression of EP3 was examined by means of RT-PCR and immunohistochemistry in wild-type mice, as well as by means of 5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside staining in mice deficient in EP3 (Ptger3(-/-) mice) carrying the beta-galactosidase gene at the EP3 gene locus. EAC was induced by immunization of mice with short ragweed pollen (RW), followed by challenge with eye drops of RW, and eosinophil infiltration and eotaxin-1 mRNA expression in the conjunctiva were examined. Mice were also treated with a topical application of an EP3-selective agonist during the elicitation phase. Quantitative RT-PCR was used to detect expression of COXs and prostaglandin E synthases, and ELISA was used to measure PGE(2) production in the eyelid.


RESULTS
EP3 was constitutively expressed in conjunctival epithelium on the ocular surface. Ptger3(-/-) mice demonstrated significantly increased eosinophil infiltration in conjunctiva after RW challenge compared with wild-type mice. Consistently, significantly higher expression of eotaxin-1 mRNA was observed in Ptger3(-/-) mice. Conversely, treatment of wild-type mice with an EP3-selective agonist resulted in a significant decrease in eosinophil infiltration, which was blunted in Ptger3(-/-) mice. Expression of COX-2 and prostaglandin E synthases was upregulated and PGE(2) content was increased in the eyelids after RW challenge.


CONCLUSIONS
These data suggest that PGE(2) acts on EP3 in conjunctival epithelium and downregulates the progression of EAC.
Ueta
Mayumi
M
Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Matsuoka
Toshiyuki
T
Narumiya
Shuh
S
Kinoshita
Shigeru
S
D031164:Ambrosia / Q000276:immunology; D000818:Animals; D054413:Chemokine CCL11 / Q000378:metabolism; D003228:Conjunctiva / Q000276:immunology* / Q000473:pathology; D003233:Conjunctivitis, Allergic / Q000276:immunology* / Q000473:pathology; D051545:Cyclooxygenase 1 / Q000378:metabolism; D051546:Cyclooxygenase 2 / Q000378:metabolism; D015232:Dinoprostone / Q000031:analogs & derivatives / Q000378:metabolism* / Q000494:pharmacology; D004195:Disease Models, Animal; D004804:Eosinophils / Q000276:immunology; D004848:Epithelium / Q000276:immunology / Q000473:pathology; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases / Q000378:metabolism; D019746:Intramolecular Oxidoreductases / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D018345:Mice, Knockout; D011058:Pollen / Q000276:immunology; D000071876:Prostaglandin-E Synthases; D018078:Receptors, Prostaglandin E / Q000819:agonists / Q000235:genetics / Q000378:metabolism*; D058308:Receptors, Prostaglandin E, EP3 Subtype; D015854:Up-Regulation / Q000276:immunology; D001616:beta-Galactosidase / Q000378:metabolism
C515457:Ccl11 protein, mouse; D054413:Chemokine CCL11; C121546:ONO AE 248; C545648:Ptger3 protein, mouse; D018078:Receptors, Prostaglandin E; D058308:Receptors, Prostaglandin E, EP3 Subtype; C077623:Ptgs2 protein, mouse; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases; D001616:beta-Galactosidase; D019746:Intramolecular Oxidoreductases; D000071876:Prostaglandin-E Synthases; D015232:Dinoprostone